Levomilnacipran (BioDeep_00000837568)

   


代谢物信息卡片


2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide

化学式: C15H22N2O (246.1732042)
中文名称: 左旋体米那普仑
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2
InChI: InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3

描述信息

D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D000068760 - Serotonin and Noradrenaline Reuptake Inhibitors
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents
N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants
D002491 - Central Nervous System Agents > D000700 - Analgesics
D049990 - Membrane Transport Modulators
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents
C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent

同义名列表

2 个代谢物同义名

2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide; Levomilnacipran



数据库引用编号

14 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Takuya Nagashima, Takashi Hayakawa, Hayato Akimoto, Kimino Minagawa, Yasuo Takahashi, Satoshi Asai. Identifying Antidepressants Less Likely to Cause Hyponatremia: Triangulation of Retrospective Cohort, Disproportionality, and Pharmacodynamic Studies. Clinical pharmacology and therapeutics. 2022 06; 111(6):1258-1267. doi: 10.1002/cpt.2573. [PMID: 35258103]
  • Naoki Ito, Kazunori Sasaki, Eiji Hirose, Takayuki Nagai, Hiroko Isoda, Hiroshi Odaguchi. Preventive effect of a Kampo medicine, kososan, on recurrent depression in a mouse model of repeated social defeat stress. Gene. 2022 Jan; 806(?):145920. doi: 10.1016/j.gene.2021.145920. [PMID: 34455026]
  • Islam M Mostafa, Mahmoud A Omar, Dalia M Nagy, Sayed M Derayea. Use of Hantzsch reaction for quantitation of milnacipran as a magic treatment for fibromyalgia syndrome in human plasma and urine. Luminescence : the journal of biological and chemical luminescence. 2021 Feb; 36(1):73-78. doi: 10.1002/bio.3921. [PMID: 32706928]
  • Rasool Haddadi, Rojin Rashtiani. Anti-inflammatory and anti-hyperalgesic effects of milnacipran in inflamed rats: involvement of myeloperoxidase activity, cytokines and oxidative/nitrosative stress. Inflammopharmacology. 2020 Aug; 28(4):903-913. doi: 10.1007/s10787-020-00726-2. [PMID: 32518981]
  • Noha N Atia, Mostafa A Marzouq, Ahmed I Hassan, Walid E Eltoukhi. A new sensitive approach for spectrofluorimetric assay of Milnacipran and Amisulpride in real plasma and pharmaceutical preparations via complexation with Eosin Y dye. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy. 2019 May; 214(?):399-406. doi: 10.1016/j.saa.2019.02.071. [PMID: 30802797]
  • Islam M Mostafa, Sayed M Derayea, Dalia M Nagy, Mahmoud A Omar. An experimental ninhydrin design approach for the sensitive spectrofluorimetric assay of milnacipran in human urine and plasma. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy. 2018 Dec; 205(?):292-297. doi: 10.1016/j.saa.2018.07.040. [PMID: 30029192]
  • Hiroshi Kawai, Megumi Machida, Takuya Ishibashi, Naomi Kudo, Yoichi Kawashima, Atsushi Mitsumoto. Chronopharmacological Analysis of Antidepressant Activity of a Dual-Action Serotonin Noradrenaline Reuptake Inhibitor (SNRI), Milnacipran, in Rats. Biological & pharmaceutical bulletin. 2018; 41(2):213-219. doi: 10.1248/bpb.b17-00733. [PMID: 29386481]
  • Sarah L Martin, Andrea Power, Yvonne Boyle, Ian M Anderson, Monty A Silverdale, Anthony K P Jones. 5-HT modulation of pain perception in humans. Psychopharmacology. 2017 Oct; 234(19):2929-2939. doi: 10.1007/s00213-017-4686-6. [PMID: 28798976]
  • Can-Jun Ruan, An-Ning Li, Fang Dong, Yi-Min Zhai, Wen-Biao Li, Chuan-Yue Wang, Jose de Leon. Single- and Multiple-Dose Milnacipran Pharmacokinetics in Healthy Han Chinese Volunteers. Clinical pharmacokinetics. 2016 07; 55(7):889-896. doi: 10.1007/s40262-015-0355-2. [PMID: 26663198]
  • Christoffer Bundgaard, Elin Eneberg, Connie Sánchez. P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier in vivo. Neuropharmacology. 2016 Apr; 103(?):104-11. doi: 10.1016/j.neuropharm.2015.12.009. [PMID: 26700248]
  • Ewa Poleszak, Aleksandra Szopa, Elżbieta Wyska, Sylwia Wośko, Anna Serefko, Aleksandra Wlaź, Mateusz Pieróg, Andrzej Wróbel, Piotr Wlaź. The influence of caffeine on the activity of moclobemide, venlafaxine, bupropion and milnacipran in the forced swim test in mice. Life sciences. 2015 Sep; 136(?):13-8. doi: 10.1016/j.lfs.2015.06.008. [PMID: 26135623]
  • Laishun Chen, William M Greenberg, Carl Gommoll, Joann O'Connor, Stephen R Zukin, Antonia Periclou, Parviz Ghahramani. Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition. Clinical therapeutics. 2015 Sep; 37(9):2059-70. doi: 10.1016/j.clinthera.2015.07.005. [PMID: 26256429]
  • Yuta Yoshino, Shinichiro Ochi, Kiyohiro Yamazaki, Shunsuke Nakata, Masao Abe, Yoko Mori, Shu-ichi Ueno. Antidepressant action via the nitric oxide system: A pilot study in an acute depressive model induced by arginin. Neuroscience letters. 2015 Jul; 599(?):69-74. doi: 10.1016/j.neulet.2015.05.043. [PMID: 26007704]
  • Kyoko Uekusa, Makiko Hayashida, Youkichi Ohno. Forensic toxicological analyses of drugs in tissues in formalin solutions and in fixatives. Forensic science international. 2015 Apr; 249(?):165-72. doi: 10.1016/j.forsciint.2015.01.028. [PMID: 25700112]
  • M Kato, A Serretti, S Nonen, Y Takekita, M Wakeno, J Azuma, T Kinoshita. Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs. Translational psychiatry. 2015 Feb; 5(?):e513. doi: 10.1038/tp.2015.6. [PMID: 25710119]
  • Valérie Brunner, Bernadette Maynadier, Laishun Chen, Louise Roques, Isabelle Hude, Sébastien Séguier, Laurence Barthe, Philippe Hermann. Disposition and metabolism of [14C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats. Drug design, development and therapy. 2015; 9(?):3199-215. doi: 10.2147/dddt.s80886. [PMID: 26150694]
  • Gautam Singhvi, Abhishek Shah, Nilesh Yadav, Ranendra N Saha. Prediction of in vivo plasma concentration-time profile from in vitro release data of designed formulations of milnacipran using numerical convolution method. Drug development and industrial pharmacy. 2015 Jan; 41(1):105-8. doi: 10.3109/03639045.2013.850706. [PMID: 24164467]
  • Laishun Chen, William M Greenberg, Elimor Brand-Schieber, Julie Wangsa, Antonia Periclou, Parviz Ghahramani. Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. Drug design, development and therapy. 2015; 9(?):3293-300. doi: 10.2147/dddt.s85418. [PMID: 26150701]
  • Gautam Singhvi, Abhishek Shah, Nilesh Yadav, Ranendra N Saha. Study the effect of formulation variables on drug release from hydrophilic matrix tablets of milnacipran and prediction of in-vivo plasma profile. Pharmaceutical development and technology. 2014 Sep; 19(6):708-16. doi: 10.3109/10837450.2013.823993. [PMID: 23931031]
  • Laishun Chen, Ramesh Boinpally, William M Greenberg, Julie Wangsa, Antonia Periclou, Parviz Ghahramani. Effect of hepatic impairment on the pharmacokinetics of levomilnacipran following a single oral dose of a levomilnacipran extended-release capsule in human participants. Clinical drug investigation. 2014 May; 34(5):351-9. doi: 10.1007/s40261-014-0182-5. [PMID: 24677141]
  • Syed Mohd Danish Rizvi, Sibhghatulla Shaikh, Mahiuddin Khan, Deboshree Biswas, Nida Hameed, Shazi Shakil. Fetzima (levomilnacipran), a drug for major depressive disorder as a dual inhibitor for human serotonin transporters and beta-site amyloid precursor protein cleaving enzyme-1. CNS & neurological disorders drug targets. 2014; 13(8):1427-31. doi: 10.2174/1871527313666141023145703. [PMID: 25345508]
  • Punit B Parejiya, Bhavesh S Barot, Hetal K Patel, Pragna K Shelat, Arunkumar Shukla. Innovation of novel 'Tab in Tab' system for release modulation of milnacipran HCl: optimization, formulation and in vitro investigations. Drug development and industrial pharmacy. 2013 Nov; 39(11):1851-63. doi: 10.3109/03639045.2012.738686. [PMID: 23210688]
  • Tsuyoshi Nogami, Harumasa Takano, Ryosuke Arakawa, Tetsuya Ichimiya, Hironobu Fujiwara, Yasuyuki Kimura, Fumitoshi Kodaka, Takeshi Sasaki, Keisuke Takahata, Masayuki Suzuki, Tomohisa Nagashima, Takaaki Mori, Hitoshi Shimada, Hajime Fukuda, Mizuho Sekine, Amane Tateno, Hidehiko Takahashi, Hiroshi Ito, Yoshiro Okubo, Tetsuya Suhara. Occupancy of serotonin and norepinephrine transporter by milnacipran in patients with major depressive disorder: a positron emission tomography study with [(11)C]DASB and (S,S)-[(18)F]FMeNER-D(2). The international journal of neuropsychopharmacology. 2013 Jun; 16(5):937-43. doi: 10.1017/s1461145712001009. [PMID: 23067569]
  • Punit B Parejiya, Bhavesh S Barot, Hetal K Patel, Mehul R Chorawala, Pragna K Shelat, Arunkumar Shukla. In vivo performance evaluation and establishment of IVIVC for osmotic pump based extended release formulation of milnacipran HCl. Biopharmaceutics & drug disposition. 2013 May; 34(4):227-35. doi: 10.1002/bdd.1840. [PMID: 23463628]
  • Akihiro Takano, Christer Halldin, Lars Farde. SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study. Psychopharmacology. 2013 Mar; 226(1):147-53. doi: 10.1007/s00213-012-2901-z. [PMID: 23090625]
  • Fanying Li, Christina Chin, Julie Wangsa, John Ho. Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride. Drug metabolism and disposition: the biological fate of chemicals. 2012 Sep; 40(9):1723-35. doi: 10.1124/dmd.112.045120. [PMID: 22653299]
  • Hiroyuki Kimura, Keizo Yoshida, Mikiko Ito, Tatsuya Tokura, Wataru Nagashima, Kenichi Kurita, Norio Ozaki. Plasma levels of milnacipran and its effectiveness for the treatment of chronic pain in the orofacial region. Human psychopharmacology. 2012 May; 27(3):322-8. doi: 10.1002/hup.2230. [PMID: 22585592]
  • Michael Levine, Carrie A Truitt, Ayrn D O'Connor. Cardiotoxicity and serotonin syndrome complicating a milnacipran overdose. Journal of medical toxicology : official journal of the American College of Medical Toxicology. 2011 Dec; 7(4):312-6. doi: 10.1007/s13181-011-0167-1. [PMID: 21735310]
  • A-S Wattiez, F Libert, A-M Privat, S Loiodice, J Fialip, A Eschalier, C Courteix. Evidence for a differential opioidergic involvement in the analgesic effect of antidepressants: prediction for efficacy in animal models of neuropathic pain?. British journal of pharmacology. 2011 Jun; 163(4):792-803. doi: 10.1111/j.1476-5381.2011.01297.x. [PMID: 21371007]
  • Ruth E Curran, Christopher R J Claxton, Laura Hutchison, Paul J Harradine, Iain J Martin, Peter Littlewood. Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding. Drug metabolism and disposition: the biological fate of chemicals. 2011 Mar; 39(3):551-7. doi: 10.1124/dmd.110.036988. [PMID: 21098647]
  • Masaki Uchida, Takuya Katoh, Mutsuhiro Mori, Takuya Maeno, Kazuo Ohtake, Jun Kobayashi, Yasunori Morimoto, Hideshi Natsume. Intranasal administration of milnacipran in rats: evaluation of the transport of drugs to the systemic circulation and central nervous system and the pharmacological effect. Biological & pharmaceutical bulletin. 2011; 34(5):740-7. doi: 10.1248/bpb.34.740. [PMID: 21532166]
  • Mervyn B Forman, Paul G Sutej, Edwin K Jackson. Hypertension, tachycardia, and reversible cardiomyopathy temporally associated with milnacipran use. Texas Heart Institute journal. 2011; 38(6):714-8. doi: NULL. [PMID: 22199446]
  • Yoshitaka Mitsumori, Yuji Nakamura, Kiyotaka Hoshiai, Yukitoshi Nagayama, Satomi Adachi-Akahane, Schuichi Koizumi, Masahiko Matsumoto, Atsushi Sugiyama. In vivo canine model comparison of cardiovascular effects of antidepressants milnacipran and imipramine. Cardiovascular toxicology. 2010 Dec; 10(4):275-82. doi: 10.1007/s12012-010-9084-9. [PMID: 20680703]
  • Jeffrey A Kyle, B Deeann Dugan, Kristian K Testerman. Milnacipran for treatment of fibromyalgia. The Annals of pharmacotherapy. 2010 Sep; 44(9):1422-9. doi: 10.1345/aph.1p218. [PMID: 20716692]
  • Hisashi Higuchi. [Prediction of antidepressant response to milnacipran and fluvoxamine using pharmacogenetical methods]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology. 2010 Apr; 30(2):71-6. doi: . [PMID: 20491280]
  • Atsuko Ikenouchi-Sugita, Reiji Yoshimura, Hikaru Hori, Wakako Umene-Nakano, Nobuhisa Ueda, Jun Nakamura. Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine. Progress in neuro-psychopharmacology & biological psychiatry. 2009 Nov; 33(8):1451-3. doi: 10.1016/j.pnpbp.2009.07.028. [PMID: 19664676]
  • Brandy L Paris, Brian W Ogilvie, Julie A Scheinkoenig, Florence Ndikum-Moffor, Remi Gibson, Andrew Parkinson. In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran. Drug metabolism and disposition: the biological fate of chemicals. 2009 Oct; 37(10):2045-54. doi: 10.1124/dmd.109.028274. [PMID: 19608694]
  • Abdullah Akpinar. [Acute prostatism associated with milnacipran therapy: a case report]. Turk psikiyatri dergisi = Turkish journal of psychiatry. 2009; 20(4):403-5. doi: NULL. [PMID: 20013433]
  • Brian Dyck, Junko Tamiya, Florence Jovic, Rebecca R Pick, Margaret J Bradbury, Julie O'Brien, Jenny Wen, Michael Johns, Ajay Madan, Beth A Fleck, Alan C Foster, Binfeng Li, Mingzhu Zhang, Joe A Tran, Troy Vickers, Jonathan Grey, John Saunders, Chen Chen. Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain. Journal of medicinal chemistry. 2008 Nov; 51(22):7265-72. doi: 10.1021/jm8009537. [PMID: 18954038]
  • Michihisa Tohda, Hisae Hayashi, Monrudee Sukma, Ken Tanaka. BNIP-3: a novel candidate for an intrinsic depression-related factor found in NG108-15 cells treated with Hochu-ekki-to, a traditional oriental medicine, or typical antidepressants. Neuroscience research. 2008 Sep; 62(1):1-8. doi: 10.1016/j.neures.2008.05.007. [PMID: 18606473]
  • Michael T Isaac. Treating depression with SNRIs: who will benefit most?. CNS spectrums. 2008 Jul; 13(7 Suppl 11):15-21. doi: 10.1017/s1092852900028273. [PMID: 18622370]
  • Troy Vickers, Brian Dyck, Junko Tamiya, Mingzhu Zhang, Florence Jovic, Jonathan Grey, Beth A Fleck, Anna Aparicio, Michael Johns, Liping Jin, Hui Tang, Alan C Foster, Chen Chen. Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors. Bioorganic & medicinal chemistry letters. 2008 Jun; 18(11):3230-5. doi: 10.1016/j.bmcl.2008.04.045. [PMID: 18468895]
  • Reiji Yoshimura, Masae Mitoma, Atsuko Sugita, Hikaru Hori, Tatsuya Okamoto, Wakako Umene, Nobuhisa Ueda, Jun Nakamura. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Progress in neuro-psychopharmacology & biological psychiatry. 2007 Jun; 31(5):1034-7. doi: 10.1016/j.pnpbp.2007.03.001. [PMID: 17459550]
  • Heidi Roggen, Jan Kehler, Tine Bryan Stensbøl, Tore Hansen. Synthesis of enantiomerically pure milnacipran analogs and inhibition of dopamine, serotonin, and norepinephrine transporters. Bioorganic & medicinal chemistry letters. 2007 May; 17(10):2834-7. doi: 10.1016/j.bmcl.2007.02.054. [PMID: 17350257]
  • Katsunori Nonogaki, Kana Nozue, Tomifusa Kuboki, Yoshitomo Oka. Milnacipran, a serotonin and norepinephrine reuptake inhibitor, induces appetite-suppressing effects without inducing hypothalamic stress responses in mice. American journal of physiology. Regulatory, integrative and comparative physiology. 2007 May; 292(5):R1775-81. doi: 10.1152/ajpregu.00527.2006. [PMID: 17218444]
  • Koji Shinkai, Reiji Yoshimura, Yumiko Toyohira, Susumu Ueno, Masato Tsutsui, Jun Nakamura, Nobuyuki Yanagihara. Effect of prolonged exposure to milnacipran on norepinephrine transporter in cultured bovine adrenal medullary cells. Biochemical pharmacology. 2005 Nov; 70(9):1389-97. doi: 10.1016/j.bcp.2005.07.031. [PMID: 16153610]
  • Christian Puozzo, Simone Lens, Christian Reh, Karl Michaelis, Dominique Rosillon, Xavier Deroubaix, Dominique Deprez. Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants. Clinical pharmacokinetics. 2005; 44(9):977-88. doi: 10.2165/00003088-200544090-00007. [PMID: 16122284]
  • Keizo Yoshida, Hitoshi Takahashi, Hisashi Higuchi, Mitsuhiro Kamata, Ken-ichi Ito, Kazuhiro Sato, Shingo Naito, Tetsuo Shimizu, Kunihiko Itoh, Kazuyuki Inoue, Toshio Suzuki, Charles B Nemeroff. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. The American journal of psychiatry. 2004 Sep; 161(9):1575-80. doi: 10.1176/appi.ajp.161.9.1575. [PMID: 15337646]
  • Kazuyoshi Ueta, Takahiro Suzuki, Ichiro Uchida, Takashi Mashimo. In vitro inhibition of recombinant ligand-gated ion channels by high concentrations of milnacipran. Psychopharmacology. 2004 Sep; 175(2):241-6. doi: 10.1007/s00213-004-1808-8. [PMID: 14997275]
  • Christian Puozzo, Christian Filaquier, Grégoire Zorza. Determination of milnacipran, a serotonin and noradrenaline reuptake inhibitor, in human plasma using liquid chromatography with spectrofluorimetric detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2004 Jul; 806(2):221-8. doi: 10.1016/j.jchromb.2004.03.063. [PMID: 15171932]
  • S Neil Vaishnavi, Charles B Nemeroff, Susan J Plott, Srinivas G Rao, Jay Kranzler, Michael J Owens. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biological psychiatry. 2004 Feb; 55(3):320-2. doi: 10.1016/j.biopsych.2003.07.006. [PMID: 14744476]
  • Koji Shinkai, Reiji Yoshimura, Nobuhisa Ueda, Kana Okamoto, Jun Nakamura. Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. Journal of clinical psychopharmacology. 2004 Feb; 24(1):11-7. doi: 10.1097/01.jcp.0000104904.75206.19. [PMID: 14709941]
  • Maria B Isaac, Michael T Isaac. Effect of pindolol and milnacipran versus milnacipran and placebo on plasma prolactin and adrenocorticotrophic hormone in depressed subjects. Human psychopharmacology. 2003 Oct; 18(7):569-74. doi: 10.1002/hup.522. [PMID: 14533141]
  • Hisashi Higuchi, Keizo Yoshida, Hitoshi Takahashi, Shingo Naito, Mitsuhiro Kamata, Kenichi Ito, Kazuhiro Sato, Kei Tsukamoto, Tetsuo Shimizu, Mamoru Nakanishi, Yasuo Hishikawa. Milnacipran plasma levels and antidepressant response in Japanese major depressive patients. Human psychopharmacology. 2003 Jun; 18(4):255-9. doi: 10.1002/hup.484. [PMID: 12766929]
  • Christian Puozzo, Emmanuel Panconi, Dominique Deprez. Pharmacology and pharmacokinetics of milnacipran. International clinical psychopharmacology. 2002 Jun; 17 Suppl 1(?):S25-35. doi: 10.1097/00004850-200206001-00004. [PMID: 12369608]
  • Y Sawada, H Ohtani. [Pharmacokinetics and drug interactions of antidepressive agents]. Nihon rinsho. Japanese journal of clinical medicine. 2001 Aug; 59(8):1539-45. doi: NULL. [PMID: 11519155]
  • C Puozzo, H Albin, G Vinçon, D Deprez, J M Raymond, M Amouretti. Pharmacokinetics of milnacipran in liver impairment. European journal of drug metabolism and pharmacokinetics. 1998 Apr; 23(2):273-9. doi: 10.1007/bf03189351. [PMID: 9725493]
  • C Puozzo, N Pozet, D Deprez, P Baille, H L Ung, P Zech. Pharmacokinetics of milnacipran in renal impairment. European journal of drug metabolism and pharmacokinetics. 1998 Apr; 23(2):280-6. doi: 10.1007/bf03189352. [PMID: 9725494]
  • C Puozzo, B E Leonard. Pharmacokinetics of milnacipran in comparison with other antidepressants. International clinical psychopharmacology. 1996 Sep; 11 Suppl 4(?):15-27. doi: 10.1097/00004850-199609004-00003. [PMID: 8923123]
  • M Ansseau, P Papart, B Troisfontaines, F Bartholomé, M Bataille, G Charles, M Schittecatte, P Darimont, J M Devoitille, J De Wilde. Controlled comparison of milnacipran and fluoxetine in major depression. Psychopharmacology. 1994 Feb; 114(1):131-7. doi: 10.1007/bf02245454. [PMID: 7846195]
  • J Caron, C Libersa, J R Hazard, D Lacroix, E Facq, L Guedon-Moreau, V Fautrez, A Solles, C Puozzo, S Kacet. Acute electrophysiological effects of intravenous milnacipran, a new antidepressant agent. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 1993 Dec; 3(4):493-500. doi: 10.1016/0924-977x(93)90274-p. [PMID: 8111222]
  • C Palmier, C Puozzo, T Lenehan, M Briley. Monoamine uptake inhibition by plasma from healthy volunteers after single oral doses of the antidepressant milnacipran. European journal of clinical pharmacology. 1989; 37(3):235-8. doi: 10.1007/bf00679776. [PMID: 2612537]